A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumors|Metastatic Colon Cancer|Metastatic Breast Cancer|Triple Negative Breast Cancer|HER2-negative Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Rectal Cancer
Interventions: DRUG: Fruquintinib (HMPL-013)
Sponsor: Hutchmed